Eurofins Scientific buys Beacon Discovery

By The Science Advisory Board staff writers

February 18, 2021 -- Bioanalytical testing firm Eurofins Scientific has purchased Beacon Discovery, a contract research organization focused on G-protein coupled receptor (GPCR) research.

Beacon has a large portfolio of validated in vitro pharmacology, "absorption, distribution, metabolism, and excretion" (collectively known as ADMET), and chemistry services for integrated drug discovery clients. The deal is expected to close in coming weeks, according to Eurofins.

The acquisition will support Eurofins' efforts to boost its drug discovery and new therapeutics offerings, it said.

Financial details of the acquisition were not disclosed.

Eurofins CDMO expands drug product operations in Canada
Eurofins contract development and manufacturing organization (CDMO) has expanded its existing drug product operation capabilities with a new manufacturing...
Eurofins DiscoverX expands program with Catalent
Eurofins DiscoverX has expanded its contract research organization certification program for bioassays with Catalent Biologics as the North American provider.
Eurofins Discovery supports COVID-19 research
Eurofins Discovery has announced that it aims to accelerate COVID-19 antiviral drug discovery research.

Copyright © 2021

Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter